Fosmidomycin is a molecule that possesses antimalarial and antibacterial activity.
The co-development project follows reports of the emergence of artemisinin resistance on the Thai-Cambodian border.
Jomaa Pharma MD David Hutchinson said that a concept study of fosmidomycin coupled with piperaquine was being planned for later this year in Thailand which will be followed by Phase II studies in children and toddlers in sub-Saharan Africa.
"We are also collaborating with the European and Developing Countries Clinical Trials Partnership (EDCTP) to develop NACT products based on fosmidomycin under an existing grant," Hutchinson said.
MMV CEO Tim Wells said they are very interested in working with Jomaa Pharma and the opportunity this gives us to develop fosmidomycin as a novel antimalarial agent.